Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exenatide.

A Barnett1

  • 1Birmingham Heartlands Hospital, Undergraduate Centre, Bordesley Green East, Birmingham, B9 5SS, UK. anthony.barnett@heartofengland.nhs.uk

Expert Opinion on Pharmacotherapy
|October 13, 2007
PubMed
Summary
This summary is machine-generated.

Exenatide, a GLP-1 receptor agonist, improves glycemic control and promotes weight loss in Type 2 diabetes patients. Long-term studies show sustained benefits and good tolerability, with nausea being the main side effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time to Splenic Embolisation in Trauma Patients Arriving at a Major Trauma Centre In-Hours or Out-of-Hours: A UK Multicentre Study.

Cardiovascular and interventional radiology·2026
Same author

Limited Evidence for Depth Specialism in Isolated Seamount Reef Predators.

Ecology and evolution·2025
Same author

A discrete choice experiment to elicit preferences for a chronic disease screening programme in Queensland, Australia.

Public health·2024
Same author

Functional outcomes after Medial Patellofemoral Ligament Reconstruction show inverted J-shaped relation with Body Mass Index.

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA·2023
Same author

'A circuit breaker' - Interrupting the alcohol autopilot: A qualitative exploration of participants' experiences of a personalised mHealth approach bias modification intervention for alcohol use.

Addictive behaviors reports·2022
Same author

Shark depredation: future directions in research and management.

Reviews in fish biology and fisheries·2022
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

CURRENT ADVANCES IN PHARMACOTHERAPEUTIC STRATEGIES FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Exenatide mimics glucagon-like peptide-1 (GLP-1), a natural hormone.
  • GLP-1 analogs improve glycemic control through multiple mechanisms.

Purpose of the Study:

  • To evaluate exenatide's efficacy and safety in Type 2 diabetes management.
  • To assess long-term effects on glycemic control and body weight.

Main Methods:

  • Phase III clinical trials and open-label extensions.
  • Exenatide added to metformin, sulfonylureas, or combination therapy.
  • Assessment of glycated haemoglobin, plasma glucose, and body weight.

Main Results:

  • Significant reductions in HbA1c, fasting, and postprandial glucose.

Related Experiment Videos

  • Average weight loss of 2 kg over 30 weeks, with sustained reductions over 3 years.
  • Generally well-tolerated, with nausea most common side effect, manageable with dose titration.

    • Conclusions:

    • Exenatide effectively improves glycemic control and reduces body weight in Type 2 diabetes.
    • Sustained efficacy and progressive weight loss observed over 3 years.
    • Exenatide offers an alternative to insulin, potentially reducing hypoglycemia and weight gain risks.